Survodutide Once Weekly for the Treatment of Adults with Obesity.

le Roux CW, Wharton S, Startseva E, Kloer IM, Hussain SA, Unseld A, Bozkurt B, Ard JD, Bays HE, Bogdański P, Ekinci EI, Jastreboff AM and 12 more

Show all authors

Ji L, Ogawa W, Pedersen SD, Pietiläinen KH, Sattar N, Seufert J, Stenlöf K, van Beek AP, Vangoitsenhoven R, Brueckmann M, Younes R, Kaplan LM

The New England journal of medicine7 Jun 2026Cited by 10 (Europe PMC)

PMID42253238DOI10.1056/nejmoa2600751PepBankPUB-42253238

Publisher page PubMedAsk about this study

Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

01HumanRandomized controlled trialEfficacy outcome
In adults with obesity without diabetes, survodutide at up to 3.6 mg weekly reduced body weight more than placebo at week 76.
In plain wordsIn adults with obesity, survodutide at up to 3.6 mg weekly reduced body weight more than placebo after 76 weeks.
Peptide
Survodutide
Outcome
DecreasePercent change in body weight at week 76
Study
n: not reported in source
Comparator
Placebo
Analysis
Primary
Outcome group
Body weight · Metabolic and weight
Studied dose
up to 3.6 mg once weekly · subcutaneous · 76 weeksAs given in this study (human).
Measurements
Mean body weight change
−12.2%
survodutide 3.6 mg
Mean body weight change
−5.4%
placebo
Source sentences
Summary
At week 76, the mean change in body weight from baseline according to the treatment-regimen estimand was -12.2% (95% confidence interval [CI], -13.6 to -10.8) in the 3.6-mg group, -13.0% (95% CI, -14.4 to -11.6) in the 6.0-mg group, and -5.4% (95% CI, -6.9 to -4.0) in the placebo group
2 context sentences(design, population, supporting numbers)
Summary · context
The two primary end points were the percent change in body weight and a reduction in body weight of at least 5% from baseline to week 76.
Summary · context
Among 725 participants (241 in the 3.6-mg survodutide group, 242 in the 6.0-mg survodutide group, and 242 in the placebo group), the mean age was 47.1 years; 294 participants (40.6%) were men.
Report a problemFND-4225323801
02HumanRandomized controlled trialEfficacy outcome
In adults with obesity without diabetes, survodutide at up to 6.0 mg weekly reduced body weight more than placebo at week 76.
In plain wordsIn adults with obesity, survodutide at up to 6.0 mg weekly reduced body weight more than placebo after 76 weeks.
Peptide
Survodutide
Outcome
DecreasePercent change in body weight at week 76
Study
n: not reported in source
Comparator
Placebo
Analysis
Primary
Outcome group
Body weight · Metabolic and weight
Studied dose
up to 6.0 mg once weekly · subcutaneous · 76 weeksAs given in this study (human).
Measurements
Mean body weight change
−13%
survodutide 6.0 mg
Mean body weight change
−5.4%
placebo
Source sentences
Summary
At week 76, the mean change in body weight from baseline according to the treatment-regimen estimand was -12.2% (95% confidence interval [CI], -13.6 to -10.8) in the 3.6-mg group, -13.0% (95% CI, -14.4 to -11.6) in the 6.0-mg group, and -5.4% (95% CI, -6.9 to -4.0) in the placebo group
2 context sentences(design, population, supporting numbers)
Summary · context
The two primary end points were the percent change in body weight and a reduction in body weight of at least 5% from baseline to week 76.
Summary · context
Among 725 participants (241 in the 3.6-mg survodutide group, 242 in the 6.0-mg survodutide group, and 242 in the placebo group), the mean age was 47.1 years; 294 participants (40.6%) were men.
Report a problemFND-4225323802
03HumanRandomized controlled trialEfficacy outcome
In adults with obesity without diabetes, more participants on survodutide up to 3.6 mg weekly than on placebo had weight reduction of at least 5%.
In plain wordsIn adults with obesity, more people on survodutide up to 3.6 mg weekly than on placebo lost at least 5% of body weight.
Peptide
Survodutide
Outcome
IncreaseWeight reduction of at least 5% at week 76
Study
n: not reported in source
Comparator
Placebo
Analysis
Primary
Outcome group
Body weight · Metabolic and weight
Studied dose
up to 3.6 mg once weekly · subcutaneous · 76 weeksAs given in this study (human).
Measurements
Participants with weight reduction of at least 5%
72.6%
survodutide 3.6 mg
Participants with weight reduction of at least 5%
46.3%
placebo
Source sentences
Summary
72.6%, 71.9% and 46.3% of the participants, respectively, had weight reduction of at least 5% (P<0.001 for all comparisons with placebo).
2 context sentences(design, population, supporting numbers)
Summary · context
At week 76, the mean change in body weight from baseline according to the treatment-regimen estimand was -12.2% (95% confidence interval [CI], -13.6 to -10.8) in the 3.6-mg group, -13.0% (95% CI, -14.4 to -11.6) in the 6.0-mg group, and -5.4% (95% CI, -6.9 to -4.0) in the placebo group
Summary · context
Among 725 participants (241 in the 3.6-mg survodutide group, 242 in the 6.0-mg survodutide group, and 242 in the placebo group), the mean age was 47.1 years; 294 participants (40.6%) were men.
Report a problemFND-4225323803
04HumanRandomized controlled trialEfficacy outcome
In adults with obesity without diabetes, more participants on survodutide up to 6.0 mg weekly than on placebo had weight reduction of at least 5%.
In plain wordsIn adults with obesity, more people on survodutide up to 6.0 mg weekly than on placebo lost at least 5% of body weight.
Peptide
Survodutide
Outcome
IncreaseWeight reduction of at least 5% at week 76
Study
n: not reported in source
Comparator
Placebo
Analysis
Primary
Outcome group
Body weight · Metabolic and weight
Studied dose
up to 6.0 mg once weekly · subcutaneous · 76 weeksAs given in this study (human).
Measurements
Participants with weight reduction of at least 5%
71.9%
survodutide 6.0 mg
Participants with weight reduction of at least 5%
46.3%
placebo
Source sentences
Summary
72.6%, 71.9% and 46.3% of the participants, respectively, had weight reduction of at least 5% (P<0.001 for all comparisons with placebo).
2 context sentences(design, population, supporting numbers)
Summary · context
At week 76, the mean change in body weight from baseline according to the treatment-regimen estimand was -12.2% (95% confidence interval [CI], -13.6 to -10.8) in the 3.6-mg group, -13.0% (95% CI, -14.4 to -11.6) in the 6.0-mg group, and -5.4% (95% CI, -6.9 to -4.0) in the placebo group
Summary · context
Among 725 participants (241 in the 3.6-mg survodutide group, 242 in the 6.0-mg survodutide group, and 242 in the placebo group), the mean age was 47.1 years; 294 participants (40.6%) were men.
Report a problemFND-4225323804
05HumanRandomized controlled trialSafety outcome
In adults with obesity without diabetes, no deaths were reported in the trial.
In plain wordsIn adults with obesity, no deaths were reported in the survodutide or placebo groups of this trial.
Peptide
Survodutide
Outcome
No significant changeDeaths
Study
n = 725
Outcome group
Mortality · Whole body
Studied dose
3.6 mg or 6.0 mg once weekly · subcutaneous · 76 weeksAs given in this study (human).
Source sentences
Summary
No deaths were reported.
1 context sentence(design, population, supporting numbers)
Summary · context
Among 725 participants (241 in the 3.6-mg survodutide group, 242 in the 6.0-mg survodutide group, and 242 in the placebo group), the mean age was 47.1 years; 294 participants (40.6%) were men.
Report a problemFND-4225323807
06HumanRandomized controlled trialSafety outcome
In adults with obesity without diabetes, gastrointestinal symptoms were more frequent with survodutide up to 3.6 mg weekly than with placebo.
In plain wordsIn adults with obesity, stomach and gut symptoms were more common with survodutide up to 3.6 mg weekly than with placebo.
Peptide
Survodutide
Outcome
IncreaseGastrointestinal adverse events
Study
n: not reported in source
Comparator
Placebo
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
up to 3.6 mg once weekly · subcutaneous · 76 weeksAs given in this study (human).
Measurements
Gastrointestinal adverse events
80.9%
survodutide 3.6 mg
Gastrointestinal adverse events
47.9%
placebo
Source sentences
Summary
The most common adverse events were gastrointestinal symptoms (typically mild to moderate), which occurred in 80.9% of the participants in the 3.6-mg group, in 89.7% of those in the 6.0-mg group, and in 47.9% of those in the placebo group.
1 context sentence(design, population, supporting numbers)
Summary · context
Among 725 participants (241 in the 3.6-mg survodutide group, 242 in the 6.0-mg survodutide group, and 242 in the placebo group), the mean age was 47.1 years; 294 participants (40.6%) were men.
Report a problemFND-4225323805
07HumanRandomized controlled trialSafety outcome
In adults with obesity without diabetes, gastrointestinal symptoms were more frequent with survodutide up to 6.0 mg weekly than with placebo.
In plain wordsIn adults with obesity, stomach and gut symptoms were more common with survodutide up to 6.0 mg weekly than with placebo.
Peptide
Survodutide
Outcome
IncreaseGastrointestinal adverse events
Study
n: not reported in source
Comparator
Placebo
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
up to 6.0 mg once weekly · subcutaneous · 76 weeksAs given in this study (human).
Measurements
Gastrointestinal adverse events
89.7%
survodutide 6.0 mg
Gastrointestinal adverse events
47.9%
placebo
Source sentences
Summary
The most common adverse events were gastrointestinal symptoms (typically mild to moderate), which occurred in 80.9% of the participants in the 3.6-mg group, in 89.7% of those in the 6.0-mg group, and in 47.9% of those in the placebo group.
1 context sentence(design, population, supporting numbers)
Summary · context
Among 725 participants (241 in the 3.6-mg survodutide group, 242 in the 6.0-mg survodutide group, and 242 in the placebo group), the mean age was 47.1 years; 294 participants (40.6%) were men.
Report a problemFND-4225323806

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 3NCT06066515

A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who do Not Have Diabetes to Lose Weight

Boehringer Ingelheimn = 72625 Nov 2023 to 20 Feb 2026

Obesity

Trial page ClinicalTrials.govUpdated 12 Mar 2026

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
9 Oct 2026, 19:08 UTC
Study results updated
Version 1
9 Oct 2026, 03:06 UTC
First added · source update from Europe PMC

PepBank is a research reference. Talk to a doctor before you use any peptide.